Frequently Asked Question
DSIP is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee, where it is listed as 'Emideltide.' Removal did not place it on the approved list.1 2 3
Get notified
The vote is advisory. The decision that shapes access comes later - if and when the FDA opens a formal public comment window. Most people never hear it opened. Join the list and we'll tell you the instant it does, with step-by-step instructions to file a comment that counts.
